Business Context and Reporting Period
This Form 8-K was filed by Anixa Biosciences, Inc. on November 8, 2024. The filing serves as a Regulation FD disclosure regarding a significant clinical development update.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress rather than financial performance.
Material Changes
- Clinical Data Update: The Company and The Cleveland Clinic Foundation presented new, updated positive data for the Phase 1 study of its breast cancer vaccine.
- Event Details: The data was presented by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic, following a presentation on November 8, 2024.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding future clinical trial results and expectations. Management cautions that actual results may differ materially due to risks and uncertainties, including those detailed in the Company's most recent Form 10-K and Form 10-Q. No specific financial guidance or revised outlook was provided in this document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the full text of the clinical data announcement.
- Examine Exhibit 99.2 (Presentation Poster) for detailed scientific data regarding the Phase 1 breast cancer vaccine study.
- Consult the most recent Form 10-K or 10-Q for current financial status, cash runway, and risk factors, as this 8-K does not contain financial statements.